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espite many organized health initiatives and critically acclaimed guidelines for proper management of 
asthma therapy, there is still a large population of severe asthmatics having an uncontrolled disease. 
Severe persistent asthma, characterized by chronic airway inflammation, increased eosinophils and 
serum IgE is currently managed by using inhaled corticosteroids. It is quite challenging to get the best treatment 
guidelines for bronchial asthma in severe asthmatics, particularly in the presence of steroid resistance and the 
non-responsiveness to β-agonists. For that purpose, other methodologies are required to reverse the 
uncontrolled airway remodeling in steroid-resistant severe asthma. These advanced alternative approaches 
should be able to treat asthma symptoms and to improve the inflammatory conditions underlying characteristic 
pathological features of asthma. The current review focuses and summarizes the alternative approaches used 
in severe asthma patients. Agents targeting inflammatory cytokines, phosphodiesterase inhibitors, antibodies, 
oligonucleotides, stem cells, and target drug delivery using gene silencing, offer promise in treating severe 
asthma. 
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Introduction  
Asthma 
Asthma is a chronic inflammatory disorder of the airways 
with a high global prevalence, affecting over 400 million 
people worldwide [1]. Airway obstruction and airway 
hyper-responsiveness are characteristic features of 
asthma, caused by multiple inflammatory reactions that 
induce numerous episodes of breathlessness and 
wheezing [2]. Essential inflammatory cells (activated Th2 
lymphocytes, B cells, infiltrating eosinophils, 
degranulated mast cells, basophils), inflammatory 
mediators (IgE), cytokines, histamines, leukotrienes, and 
prostanoids) and structural cells of the airways 
(epithelial, airway smooth muscle, endothelial cells, and 
fibroblasts) play a vital role in the pathophysiology of 
asthma [3,4]. Of these, the T cells control the regulation 
of the inflammatory reactions accountable for the 
pathophysiology of asthma. Th-2 mediated responses 
are primarily active during the intermittent stages of 
asthma, while Th-1 mediated responses play a 
significant role in the severe advanced stages of asthma. 
Increased number of Th2 cells in the asthmatic airways 
induces the release of specific cytokines, interleukin IL-
4, IL-5, IL-9, and IL-13, thereby stimulating eosinophilic 
inflammation and production of IgE cells [5]. These 
pathophysiological reactions are usually triggered by a 
variety of factors, including allergen exposure, seasonal 
variations, viral respiratory infections, or exercise 
intolerance [1]. The airway remodeling in asthma is 
proportional to the severity of the disease. It influences 
the structural and functional integrity of the large and 
small airways causing loss of epithelial cell integrity, 
fibrosis, goblet cell hyperplasia, and increased smooth 
muscle cell mass and airway vascularity [3-7]. 
Chronic Obstructive Pulmonary Diseases (COPD) 
COPD is defined by persistent and irreversible airflow 
limitation, which is usually progressive and associated 
with abnormal inflammatory responses in the airways 
and lung to noxious particles or gases [2]. It has been 
estimated that COPD in 2030 will be the third foremost 
cause of mortalities worldwide [8,9]. The chronic airflow 
limitation in COPD may induce emphysema due to 
parenchymal tissue destruction and small airway fibrosis 
[2]. These structural changes and underlying 
inflammatory responses lead to loss of alveolar 
connections to small airways and decrease elastic lung 
recoil function. Inflammatory reactions in COPD are 
driven by a combination of macrophages, neutrophils, 
CD8+ T lymphocytes, dendritic cells, and B lymphocytes 
with neutrophils and B lymphocytes predominating in 
severe COPD cases [10,11]. Additional structural 
changes in COPD include an increased number of goblet 
cells and mucus hypersecretion, bronchiolar thickening, 
fibrosis, luminal inflammatory exudate, and obstructive 
bronchiolitis. The irreversible damage of respiratory 
bronchioles, and gas-exchanging air spaces (alveolar 
ducts, alveolar sacs, and alveoli) decreases the surface 
area of respiratory membrane available for gas transfer 
consequently reducing the amount of gases that can be 
transferred across in a given time, resulting in hypoxemia 
and hypercapnia [2,12]. Exacerbations constitute a 
further development of the inflammatory response in the 
airways of COPD subjects and may be activated by 
infection with microbes or by environmental impurities 
[13]. During COPD exacerbation, there is an increased 
inflation and air trapping, with a decreased rate of 
exhalation, thereby resulting in enhanced dyspnea [14]. 
There is also a deterioration of the ventilation-perfusion 
process, resulting in acute hypoxemia [2]. 
Role of Corticosteroids in Asthma and COPD 
Corticosteroids are considered to be the most potent and 
effective anti-inflammatory medications currently 
available for the symptomatic control and maintenance 
of atopic or non-atopic asthma, as recommended by 
GINA guidelines [1]. Corticosteroids act by blocking the 
late-phase response to allergens, reduce airway hyper-
responsiveness, and prevent inflammatory cell 
infiltration. Inhaled corticosteroids (ICS) are particularly 
beneficial in subjects with mild or moderate asthma [15]. 
ICS reduce the severity of symptoms, improve lung 
function, and decrease bronchial hyper-responsiveness 
(BHR), exacerbations, and airway wall remodeling. 
Besides, they also mitigate bronchial-epithelium 
abnormalities, bronchial inflammation, and inflammatory 
cell infiltration [16]. Corticosteroids exert their action 
through the cytosolic glucocorticoid receptor, which, after 
activation, is translocated into the nucleus where it either 
drives the expression of anti-inflammatory genes or limits 
the activity of nuclear factor kappaB (NF-κB), activator 
protein 1 (AP-1) or mitogen-activated protein kinase 
MAP kinase. A failure to respond to corticosteroid 
therapy may be caused by decreased expression and 
function of glucocorticoid receptors or elevated activation 
of inflammatory pathways [17]. ICS are first-line therapy 
for long-term control of persistent asthma, short courses 
of oral systemic corticosteroids are often used to gain 
prompt control of the disease when initiating long-term 
treatment for severe persistent asthma. 
Bronchodilators are the foundation for the COPD 
treatment. The beta-2 (β2) adrenergic receptors located 
on the periphery of smooth muscle cells inside the 
bronchioles are directly activated by β2-agonists, 
thereby initiating changes in biochemical pathways 
resulting in an increased production of the cyclic 
adenosine monophosphate (cAMP) within cells. 
Elevated levels of cAMP trigger bronchodilation, 
whereas the reduced levels may result in 
bronchoconstriction in bronchioles. Activation of β2-
adrenergic receptors with β2-agonists leads to smooth 
muscle relaxation, and bronchodilation [2,18]. Short-
acting β2-agonists (e.g., salbutamol) are useful for 4 to 6 
hours and are usually used “on-demand” by COPD 
patients to relieve acute symptoms. Long-acting β2-
agonists (LABAs, e.g., formoterol and salmeterol) result 
in bronchodilation for at least 12 hours after a single 
dose. Long-acting bronchodilators are usually 
recommended for patients with moderate COPD. ICS 
are introduced later in the treatment plan, for subjects 
with acute COPD and medical history of relapses, and at 
higher doses, than prescribed for asthma [2]. Both the 
Gold Standard/International Guidelines treatment 
(GOLD) and the European Respiratory Society 
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(ERS)/American Thoracic Society (ATS) guidelines 
recommend the use of oral or parenteral corticosteroids 
for the treatment of exacerbations [19]. Data shows that 
these agents reduce the likelihood of treatment failure, 
shorten hospital stays, improve forced expiratory volume 
in 1 second (FEV1), ameliorate breathlessness, and 
balance blood gases [20]. After inhalation, the 
corticosteroids stimulate the glucocorticoid receptors, 
and reduce the expression of genes involved in 
inflammatory responses. Although ICS is recommended 
in patients with Stage III or Stage IV COPD, but if the 
patient experience repeated exacerbations, they do not 
appear to have any effect on inflammation in COPD. 
However, an improvement in overall health status has 
been reported [21]. 
Refractory Asthma and COPD 
ICS are widely used in controlling the inflammatory 
reactions involved in airway hyper-responsiveness and 
are also recommended in patients with acute and long-
lasting asthma. However, patients with severe persistent 
asthma continue to remain symptomatic, albeit the 
administration of high-dose ICS and LABA, and this 
places considerable restrictions on the management of 
poorly controlled asthma. Increasing the prescribed dose 
of ICS can result in systemic adverse effects. The 
effectiveness of ICS at low or moderate doses is usually 
improved if given along with long-acting β2 agonists, and 
such combinations are successfully used in the 
treatment/management of moderate-to-severe asthma in 
various tailored doses [22]. However, these 
combinations are not effective in all the asthmatic 
patients, as a sub-group of severe asthmatic patients (5-
10%) do not respond to the usual corticosteroid therapy 
[23,24]. This group is the main contributor to the high 
health care expenditure (40–50% of medical care costs), 
as a result of increased and frequent hospitalization, and 
an enhanced and multiple usages of drugs and inhalers 
due to asthma exacerbations [25]. 
In asthma, corticosteroid resistance is identified by a 
lack of lung function improvement of more than 15% after 
treatment with 30-40 mg daily prednisolone for 2- weeks; 
however, it is scarce that a complete steroid resistance 
has been reported [21]. Refractory or corticosteroid 
resistant asthma is characterized by a failure to improve 
the forced expiratory volume in 1s by >=15% from a 
reference value of <=75% expected even after 14 days 
of administration with 40 mg prednisolone by mouth 
although representing >15% convertibility to an inhaled 
β2 agonist [26]. However, in COPD, ICS are found to 
provide minimal benefit, even if airway and lung 
inflammation was present. The treatment regimen used 
in COPD mostly involves similar drugs that are 
prescribed for asthma management, despite both 
diseases belong to two very different pathologies. ICS 
are not generally indicated as a monotherapy for COPD, 
but are mostly used in combination with regular long-
acting bronchodilators usually being restricted to patients 
with severe COPD and repeated exacerbations [2]. 
Despite this, there is a widespread use of ICS in patients 
with the more moderate disease [27-30]. ICS treatment 
is used in two scenarios in COPD: in case of mixed 
asthma and COPD and COPD exacerbations, despite 
optimal bronchodilator treatment as this phenotype 
involves increased eosinophils similar to asthma [31]. In 
contrast to asthma, patients with COPD respond poorly 
to either ICS or oral corticosteroids because they were 
not found to be effective in inhibiting disease 
progression. However, a reduction in exacerbation 
frequency has been widely reported [32], but a significant 
decrease in inflammatory cells or mediator levels in the 
airways of patients with COPD has not been observed 
[33]. Therefore, functionally, corticosteroids do not seem 
to add much value in the treatment of COPD either in 
terms of improving lung function or controlling underlying 
inflammation [34]. This inadequate response in COPD 
and resistance in asthma has led to an increase in 
preclinical research and clinical studies for the 
advancement of other antiphlogistic drugs. 
It is interesting to note that the corticosteroid 
resistance can also be found in other chronic 
inflammatory conditions [35]. Several mechanisms are 
thought to induce steroid resistance, including alterations 
in glucocorticoid receptors, abnormalities in histone 
acetylation, presence of lipocortin-1 antibodies, and 
pharmacokinetic abnormalities [36]. The addition of long-
acting inhaled β2-agonists is believed to enhance the 
antiphlogistic effects of corticosteroids through cellular 
and molecular interactions [37]. However, this is relevant 
to the patients who have inherent defects in the nuclear 
localization of glucocorticoid receptors [38]. The 
unavoidable health care costs for the treatment of 
steroid-resistant patients who do not respond adequately 
to conventional and standard anti-inflammatory 
therapies is a required field for research not only in 
asthma but also in other chronic inflammatory diseases. 
The examination is increasingly being taken up in this 
area with a focus on alternative treatment options since 
the current regimen is not very advantageous in these 
subjects. The present review article attempts to 
understand some of the alternative treatment options for 
steroid unresponsive inflammatory diseases, including 
asthma and COPD. Cell-based therapies, epigenetic 
targets, and more importantly gene silencing 
approaches, will be discussed.     
Methods 
Literature search strategy and selection criteria 
A logical search was carried out from PubMed national 
library of medicine (NLM), Web of Science, Google 
Scholar, ScienceDirect, Researchgate, and Google Web 
Browser by providing key terms "asthma, COPD, 
therapies, epigenetics, and gene silencing." To obtain a 
broad range of articles, we initially screened thousands 
of scientific manuscripts and gave particular attention to 
reports on clinical trials. The retrieved literature was 
further screened for the inclusion according to their 
contents. The reference lists of clinical trials were also 
screened, and relevant articles were included. The 
systematic review from the Global Initiative for Asthma 
(GINA) [1], Global Initiative for Chronic Obstructive Lung 
Diseases (GOLD) [2], and Expert Panel Report 3 
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(Guidelines for the Diagnosis and Management of 
Asthma) were also included [6]. A total of more than 109 
peer-reviewed research articles were selected to write 
up this review. 
Discussion 
Stem Cell Therapy for Asthma and COPD 
Stem cells, with their exceptional ability of self-replicating 
for an indefinite period, offer an enormous scope in the 
treatment of COPD [39,40]. Stem cells are associated 
with tissue homeostasis and restoration of the airways 
and may be localized in specific areas within the distal 
airways. Stem cells can be isolated from blood, bone 
marrow or adipose tissues (endothelial progenitor cells, 
mesenchymal stem cells) [41-43]. Among these, the 
mesenchymal stem cells (MSCs) are mostly used 
because of the ease of harvesting from the tissues and 
their extensive pleiotropic properties [44]. 
In severe asthma patients, asthma symptoms remain 
poorly controlled despite the use of corticosteroids in 
combination with bronchodilators. Stem cell therapy has 
been used in various diseases; however, studies in 
asthma are limited to animal models. Many studies have 
evaluated the effects of MSCs in murine asthma models 
by administering intravenous tail vein injection of human 
mesenchymal stem cells (hMSCs, up to 1×106). A 
reduction in eosinophilic inflammation was found 
following the MSCs administration before sensitization 
as well as after allergen challenge [45-49]. A decrease in 
Th2 cytokines IL-4 and IL-5 was reported in 
bronchoalveolar lavage fluid (BALF) [50]. A reduction in 
serum IgE or allergen-specific IgE was observed in 
ovalbumin (OVA) sensitized murine model of chronic 
asthma phenotype [51]. By using human bone marrow-
derived MSCs (BM-MScs), in OVA-induced airway 
hyper-responsiveness, a decrease in BALF inflammatory 
cytokines such as IL-5, IL-13, IFNγ, and serum IgE levels 
was observed. Similar observations, along with 
decreased nasal inflammation, were also reported when 
mouse MSCs were used [52]. The hMSCs are 
multipotent cells in vitro that have been shown to reduce 
inflammation and can reverse airway remodeling when 
infused into an in vivo chronic asthma model. 
Previously, it has been demonstrated that MSCs can 
produce IL-1Rα, which blocks macrophage activation 
through IL-1α, IL-1β, and TGF-β, which suppresses 
macrophage and T cell activation [53-55]. Due to the 
ability of MSCs to alter the immune system by 
decreasing inflammation and promoting wound healing, 
MSC-based therapy represents a potential therapy for 
asthma. Utilizing OVA-sensitization, an in vivo murine 
model of chronic asthma phenotype was produced, with 
and without hMSC infusion therapy. The hMSCs 
effectively influence the remodeling by reversing 
excessive amounts of extracellular matrix (ECM) 
deposition, more specifically by decreasing collagen I, 
collagen III, and changing the hyaluronan synthesis [56]. 
Diminished airway hyper-responsiveness, decreased 
eosinophilic inflammation, and Th2 to Th1 switching was 
also reported in OVA-induced asthma models [57]. Most 
of these studies reported histological improvements in 
lung tissues and clinically relevant reduction in airway 
hyper-responsiveness. However, more clinical studies 
are needed not only to assess the potential advantage of 
these cells in human subjects but also to prevent asthma 
exacerbations and further airway remodeling. Utilizing 
burrowing nanotubes, it was observed that MSCs 
expressing elevated Miro1 not only successfully reduced 
airway hyper-responsiveness to a greater extent but also 
decreased lung IL-5, IL-13, and a meager amount of 
inflammatory cell infiltration [58]. These MSCs also 
reduced collagen deposition and mucus hyper secretion 
in an OVA-induced murine asthma model. So far, MSCs 
indicate a decrease in eosinophilia and Th2 induced 
inflammation in allergic responses involved in asthma. 
However, the clinical efficacy of these studies needs to 
be established in asthma. In addition to using BM-MScs, 
other options such as using cells from adipose tissues, 
umbilical cord, or induced pluripotent stem cells (iPSCs) 
need to be evaluated entirely in both the preclinical and 
clinical studies in asthma [45,57,59]. 
The pathophysiological modifications, along with the 
enhanced inflammatory responses to stimuli associated 
with COPD, can cause endothelial cell destruction, 
accumulation of connective tissue, emphysema, and 
endothelial dysfunction. The pleiotropic properties of 
lung stem cells, in particular, the MSCs, can help in 
immunomodulation and controlling the inflammatory 
pathways in COPD. Adipose-derived stem cells were 
found to decrease emphysema through the production of 
hepatocyte growth factors [60,61]. Similarly, adipose 
stem cells also cause immunomodulation in 
inflammation paracrine pathways [62]. The value of 
endothelial progenitor cells in pulmonary vascular 
remodeling is currently being investigated in COPD, and 
the cytokines and growth factors that are involved in lung 
tissue repair are also under investigation [63]. BM-MSCs 
in a rat papain COPD model decreased the histologic 
injury and alveolar epithelial cell apoptosis after 
intravenous injection, and the vascular endothelial 
growth factor (VEGF) lung expression was also restored 
after intra-tracheal administration [64,65]. BM-MSCs in a 
mouse elastase model of COPD after intra-tracheal 
administration reduce the extent of collagen deposition 
and levels of inflammatory and profibrotic cytokines such 
as tumor necrosis factor alpha (TNF-α), transforming 
growth factor beta (TGF-β), and IL-10 [66]. 
Based on the encouraging animal studies, it can be 
anticipated that stem cells therapy can be applied as a 
potential treatment for both asthma and COPD. 
However, the data from large-scale and reliable clinical 
trials is currently infrequent. More importantly, it is crucial 
to understand further the mechanism of injected cells 
within the tissue and the tools that induce lung 
regeneration in response to cytokines or growth factors. 
The safety and efficacy of systemically administered 
cells may have potential side effects of redifferentiation 
in the cell milieu or causing pulmonary emboli; therefore, 
these aspects need further studies [44]. 
Currently, two clinical trials are being conducted to test 
the safety and efficacy of MSC-based therapy for the 
treatment of asthmatic patients [67]. 1st clinical trial 
(entitled "Allogeneic Human Cells (hMSC) Via 
Intravenous Delivery in Patients With Mild Asthma 
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(ASTEC)") is ongoing at the Miller School of Medicine, 
the University of Miami under ClinicalTrials.gov identifier: 
NCT03137199 [68]. A 2nd study is being conducted by 
researchers from the Punta Pacifica Hospital of Panama 
City entitled (Safety and Feasibility Study of Intranasal 
Mesenchymal Trophic Factor (MTF) for Treatment of 
Asthma) under ClinicalTrials.gov Identifier: 
NCT02192736 [69]. Each patient participating in the 
study would be receiving MTF intranasally, and both of 
these studies are expected to be completed by the end 
of the year 2020. 
Epigenetic Targets in Asthma and COPD 
Changes in epigenetic regulation of gene expression is 
a highly conserved evolutionary process, and any 
adaptive changes in this mechanism can be the 
foundation for several pathological modifications in 
certain prolonged respiratory infections. Recognizing the 
epigenetic targets and developing strategies to prevent 
alterations in epigenetic mechanisms has been a core 
topic of research in many preclinical studies. 
In patients with asthma, methylation of DNA has been 
described in some genes from post-mortem and lung 
biopsy samples [70]. DNA methylation was found to be 
altered in asthma and could be driven by allergen 
exposure, and this fact has been established in mouse 
asthma models. Increased alterations in global DNA 
methylation and hydroxymethylation was observed in 
lung tissue of house dust mite (HDM) sensitized 
mice.[71-73]. Additionally, mice deficient in DNA 
(cytosine-5)-methyltransferase 3A (DMT3A) in T cells 
showed higher eosinophil counts and an increased IL-13 
secretion following OVA-sensitization [74]. Acute 
inhibition of the activity of DNA methyltransferases with 
5-azacytidine was found to reduce airway hyperreactivity 
and inflammation in OVA-induced challenged mice [75]. 
Studies in asthmatic humans have shown decreased 
histone deacetylases (HDAC) and elevated histone 
acetyltransferases (HAT) activity with elevated histone 
H3 panacetylation causing enhanced expression of C-X-
C Motif Chemokine Ligand 8 (CXCL8) in airway smooth 
muscle cells [76-79]. In addition to reduced histone H3 
lysine 9 (H3K9) trimethylation, an increased expression 
of VEGF in airway smooth muscle cells was also 
reported [80]. Treatment of mice with a potent inhibitor of 
HDAC, trichostatin A, reduced airway hyper-
responsiveness. However, questions about HDAC 
inhibitors in controlling inflammation are still unanswered 
[81]. Reduced HDAC activity in asthma might cause 
elevated expression of proinflammatory genes, and 
further work is needed to establish the role of histone 
acetylation in asthma. The development of clinically 
suitable and effective HAT inhibitors is currently at a 
preliminary stage and still needs to be further evaluated. 
In COPD patients’ similar mechanisms have been 
observed involving a combination of hypermethylation at 
some loci and hypomethylation at others [82,83]. 
Differentially expressed and regulated genes found in 
COPD are involved in PI3K/Akt and Nrf2 pathways [82]. 
Hyper-methylation of phosphatase and tensin homolog 
(PTEN) and Nrf2 genes at CpG islands cause decreased 
expression and activity of these genes. While the Nrf2 is 
involved in anti-inflammation, PTEN is a regulator of 
PI3K/AKT signaling, thus indirectly contributing to the 
inflammation and airway remodeling in COPD [84,85]. 
Hypomethylation causing enhanced expression of 
HDAC6 promoter has been linked to contributing to 
epithelial dysfunction in cigarette-smoke mediated 
COPD [86]. A reduction in HDACs 2,3,5,8 and an 
increase in expression of HDACs 4, 8 have been 
reported. 
Furthermore, an increase in the acetylation of histones 
proportional to the disease severity was reported in 
inflammatory genes of COPD patients [87]. It has been 
shown previously that cigarette smoke can cause 
alterations in both HATs and HDACs, which in turn 
enhances NF-κB-dependent gene expression [88,89]. 
Increased histone acetylation of the CXCL8 gene 
regulated by NF-κB was mediated primarily due to 
variations in HDAC expressions [87].  
A combination of alterations in acetylation of histones 
and the ensuing changes in levels of HAT and HDAC, 
including changes in histone methyltransferase (HMT) 
and histone demethylase (HDM) activities lead to 
alterations in gene expression profiles even in COPD. 
These combined mechanisms operating at the cellular 
level needs to be further confirmed in future studies. 
Since epigenetics plays a significant role in the 
pathogenesis of both asthma and COPD, any drug 
targets that inhibit these changes would be beneficial, 
especially in subjects with severe disease. However, 
clinical studies in this area had been limited, and there is 
a lack of information on the effectiveness of these drugs 
in the real-world scenario. 
siRNA Technology Applications in Asthma and 
COPD 
The concept of RNA interference (RNAi) has 
increasingly become an essential method for 
understanding gene functions. It plays a significant role 
in the therapeutic gene silencing of various inflammatory 
diseases. RNAi, as a natural gene silencing 
phenomenon, has a high degree of specificity and a 
potential to silence the genes [90]. The relatively new 
small-interfering RNAs (siRNA) technology involves the 
use of synthetic double-stranded RNA (dsRNA) to 
suppress target sequences through post-transcriptional 
gene silencing [91,92]. RNAi is a post-transcriptional 
event that causes sequence-specific gene silencing 
through the introduction of dsRNA, which is 
subsequently cleaved to smaller fragments to 
approximately 20 nucleotide short double-strand 
fragments called small interfering RNAs (siRNAs) [93]. 
An enzyme complex (Dicer), is involved in RNA 
unwinding, dsRNA binding, and ribonuclease activity, 
which is targeted to specific sequences and then cleaved 
[94,95]. The siRNA is finally unwound to two ssRNAs 
called passenger and guide strands. While the 
passenger strand is degraded, the guide strand is 
included in a RNA-induced protein silencing complex 
called RISC, which eventually causes the guide strand to 
pair with a sequence in mRNA molecules, causing 
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subsequent inhibition [96]. RNAi is a novel class of 
therapeutic agents that may have more rapid 
developments when matched with other traditional 
treatment options because of its naturally occurring 
ability to block any chosen gene of interest with high 
specificity [97]. 
Lung diseases, specifically asthma, COPD, and lung 
cancer, are currently the main focus for the 
implementation of siRNA based therapeutics not only 
due to their increasing prevalence but also due to the 
ease of delivery of siRNA through intra-tracheal, intra-
pulmonary, or intra-nasal routes [98]. RNAi technology 
primarily focuses on blocking important mediators 
underlying disease pathogenesis. As mentioned 
previously, although ICS is practical in mild to moderate 
asthma for symptom control and reduction of 
exacerbations, their efficacy in severe asthma is 
debatable. Important cytokines (IL-4, IL-5, IL-13), cell 
receptors (IL-4R, and C-C chemokine receptor type 3 
(CCR3), tyrosine kinases (Syk, Lyn), and transcription 
factors (STAT1, STAT6, GATA3, NF-κB) can form 
important targets for siRNA based therapeutics in severe 
asthma [99]. Many preliminary studies in cell models 
have shown the efficacy of siRNAs in asthma, and many 
animal studies have also demonstrated the positive 
results. For example, an anti-viral siRNA against IL-4 
was found to be efficacious in reducing drug-induced 
asthma exacerbations in the mouse [100]. siRNAs 
targeted to suppressors of cytokine signaling (SOCS3) 
proteins delivered intra-nasally was found to inhibit 
asthma phenotype in mice [101]. One of the more recent 
development was a successful demonstration in phase I 
clinical trial of aerosolized Syk siRNA technology to 
inhibit inflammatory responses in asthma, this molecule 
called Excellair® is currently under phase II study [102]. 
These findings highlight the potential of siRNA 
technology in both preclinical and clinical studies. 
A combination of PDE4 and PDE7 inhibition was found 
to potentially reduce inflammatory cell activation and 
cytokine release in the lungs. The molecule TPI 1100, 
comprising of two antisense oligonucleotides that target 
the PDE4B/4D and PDE 7A mRNA, was effective in 
reducing neutrophil influx and key cytokines in COPD 
[103]. In addition, the use of "Decoy" oligonucleotides 
that decoys for transcription factors of NF-κB can reduce 
its concentration in COPD, thus minimizing inflammatory 
processes [104,105]. Potential treatment options with 
oligonucleotides, including the antisense and the RNAi 
(siRNA and miRNA) technologies are relatively new in 
the field of respiratory medicine. However, significant 
problems with these techniques remain to be addressed, 
including the stability of siRNA or miRNA molecules post-
delivery, the best delivery method, and safety during 
treatment. 
The above treatment options are primarily aimed to 
block specific signal transduction pathways or proteins 
that are involved in inflammatory responses in asthma 
and COPD that are usually present in healthy cells and 
tissues but are frequently overexpressed/under-
expressed in asthma and COPD. These revolutionary 
and targeted therapies either modify cell signaling 
events, block or activate targets or genes, and modulate 
cytokine functioning compared to the conventional 
therapies that have been used for the inflammatory 
diseases. However, the delivery of most of these 
therapies to specific sites of the body through the use of 
nanoparticles can allow these anti-inflammatory agents 
to avoid healthy cells/tissues and to get accumulated in 
the sites of inflammation to achieve a locally higher 
concentration while reducing the side effect on normal 
cells [106,107]. Besides, nanoparticles or nanocarriers 
can also help the drug/inhibitor against degradation and 
increase its half-life in the bloodstream allowing better 
bio-pharmacokinetic control in host tissues [108,109]. 
 
Conclusions and Future Outlook 
An ever-increasing line of product options and various 
preclinical and clinical trials are currently focusing on 
controlling severe asthma and chronic inflammatory 
diseases. Complete understanding of the cellular and 
molecular mechanisms will help to manage 
corticosteroid resistant individuals appropriately. Recent 
substantial therapeutic advances offer considerable 
potential in managing and treating severe uncontrolled 
persistent asthma. A combination of epigenetics and 
gene silencing technologies with optimized delivery 
strategies and biosafety holds future promise for proper 
management and treatment of asthma, COPD, and 
various other diseases that have inflammatory 
pathophysiology. 
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